Elan could receive drug royalty payments

DUBLIN-based pharmaceutical company Elan could start benefiting from royalty payments from a new drug being developed by Johnson & Johnson as soon as next year.

Elan could receive drug royalty payments

Johnson & Johnson’s injection treatment for patients with schizophrenia — Paliperidone Palmitate — was lodged as a new drug application to the Food and Drug Administration (FDA) in the US last October.

The FDA is expected to give the green light for the commercialisation of the treatment later this year.

Already a subscriber? Sign in

You have reached your article limit.

Unlimited access. Half the price.

Annual €120 €60

Best value

Monthly €10€5 / month

More in this section

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited